NOVARTIS IN GLAUCOMA DEAL WITH JAPAN'S SENJU

Swiss-based drugmaker Novartis said it had completed an agreement with Senju Pharmaceutical Co. over the development and commercialisation of a treatment for glaucoma, an eye disease. Novartis said in a statement on Wednesday that the deal was for a topical treatment of glaucoma using Y39983, a rho kinase inhibitor, under sub-licence rights granted to Senju by Mitsubishi Pharma Corp.

Reuters (http://today.reuters.com/business/newsArticle.aspx?type=health&storyID=nL09570865)